Relating to Cardiovascular Marketing.

Statin drugs, which lower cholesterol levels, dominate the pharmaceutical industry. Related StoriesDisclosing genetic risk for CHD outcomes in lower low-density lipoprotein cholesterolResearch identifies liver pathway that contributes to unwanted effects of high-unwanted fat, high-cholesterol junk food dietNew vaccine is apparently far better in reducing 'bad' LDL cholesterolThe world-wide statins market approached $12.5 billion in 2003, and two drugs, Zocor and Lipitor, controlled nearly two thirds of the lucrative US market. With many blockbuster statin items approaching patent expiration, the sector is increasing its OTC efforts.Although incredible progress has been manufactured in the field of cardiac surgery treatment in the last four decades, the clinical preventive therapy to lessen major renal and cardiocerebral problems associated with surgery, including coronary attack, stroke and renal failure, has been scant and ineffective, while these problems remain common, significant and costly, especially for older and sicker patients, said Jian-Zhong Sun, M.D., of the Anesthesiology Department at Thomas Jefferson University. Related StoriesMarriage status linked to survival outcomes following cardiac surgeryMajor UK trial to examine part of aspirin in tumor recurrenceStudy may lead to brand-new insights on use of aspirin in GI cancerIn nonsurgical settings, aspirin use is becoming a significant cornerstone in treating coronary disease, and it’s been known to enhance the outcomes of individuals with risk of coronary disease.

Comments are closed.